Trial Profile

A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Mar 2021 According to a Galecto Inc media release, the company will host an expert perspectives panel on the evolving treatment landscape for idiopathic pulmonary fibrosis (IPF) and the potential for GB0139 on March 30, 2021. The webinar will feature a presentation by Key Opinion Leader (KOL) Toby Maher, who will discuss the clinical meaning of the exciting biomarker data on GB0139 recently published in the European Respiratory Journal.
16 Mar 2021 Time frame for primary endpoint changed from 2 weeks to 30 days.
30 Nov 2020 Results presented in a Galecto Biotech Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com